Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2015-10-29 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于控股股东所持股权解押及质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding changes in the pledge and release of shares held by the controlling shareholder of the company. It details the number of shares pledged and released, the dates, and the involved parties. There is no financial report, earnings data, or management discussion. The content fits the category of a share pledge or shareholding status update, which aligns with announcements about shareholding changes or transactions in own shares. Given the focus on share pledge and release, the most appropriate classification is 'Transaction in Own Shares' (POS). The document length and content confirm it is not a full report but an announcement of share transactions.
2015-10-29 Chinese
2015年第三季度报告全文
Interim / Quarterly Report Classification · 95% confidence The document is titled "普洛药业股份有限公司 2015 年第三季度报告全文" which translates to "Puluo Pharmaceutical Co., Ltd. 2015 Third Quarter Report Full Text." It contains detailed financial data including balance sheets, profit and loss statements, cash flow data, shareholder information, and management assurances about the accuracy of the quarterly report. The presence of comprehensive financial statements and analysis for the third quarter of 2015 indicates this is a quarterly financial report. The document length is about 15,000 characters, which is consistent with a full interim/quarterly report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2015
2015-10-29 Chinese
2015年三季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2015 Third Quarter Performance Forecast' and provides estimated financial results for the period January 1, 2015 to September 30, 2015, and also for the third quarter specifically. It includes expected net profit, earnings per share, and explanations for the performance changes. It explicitly states that the forecast has not been audited and that the final financial data will be in the 2015 third quarter report. The document is relatively short (1247 characters) and is a forward-looking earnings forecast rather than actual financial results. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not a full interim report (IR) which would contain actual financial statements. Therefore, the correct classification is Earnings Release (ER). 9M 2015
2015-10-13 Chinese
西南证券股份有限公司关于公司使用部分闲置自有资金进行投资理财的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from a sponsoring securities company regarding the use of idle funds by a listed company for investment in financial products. It includes details about the investment product, approval procedures, risk assessment, and independent director opinions. The document is a verification or audit opinion related to a specific financial activity, not a full financial report or announcement of voting results. It does not contain comprehensive financial statements or quarterly/yearly results, nor is it a regulatory announcement or a presentation. The document fits the category of an Audit Report / Information (AR) as it provides an audit or verification opinion on a specific financial matter. Q3 2015
2015-10-09 Chinese
独立董事关于公司使用部分闲置自有资金进行投资理财的的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement from the independent directors of 普洛药业股份有限公司 expressing their independent opinion on the company's use of idle funds for investment purposes. It references governance guidelines and the company's internal control system but does not contain financial statements or detailed financial data. The document is short (525 characters) and serves as an independent opinion or certification rather than a full report or announcement of voting results. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified under Regulatory Filings (RNS) as it is a governance-related statement without substantive financial data or report content.
2015-10-09 Chinese
关于使用部分闲置自有资金进行投资理财的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the use of part of its idle funds for investment in financial products. It details the investment product, amount, risk control measures, and board approval. The document is short (1169 characters) and does not contain financial statements or detailed financial performance data. It is an update on a financing-related activity (investment of idle funds) rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2015-09-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.